CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).
Alan P. Venook
Consultant or Advisory Role - Bristol-Myers Squibb (U); Chugai Pharma (U); Mirna (U); Pharmacyclics (U); Roche/Genentech (U); Sanofi (U)
Research Funding - Bayer; Genomic Health; GlaxoSmithKline; Onyx; Roche/Genentech
Donna Niedzwiecki
No relevant relationships to disclose
Heinz-Josef Lenz
No relevant relationships to disclose
Federico Innocenti
No relevant relationships to disclose
Michelle R. Mahoney
No relevant relationships to disclose
Bert H. O'Neil
Consultant or Advisory Role - Roche/Genentech
James Edward Shaw
No relevant relationships to disclose
Blase N. Polite
Honoraria - Bayer/Onyx
Howard S. Hochster
Consultant or Advisory Role - Genentech; Sanofi
James Norman Atkins
No relevant relationships to disclose
Richard M. Goldberg
Consultant or Advisory Role - Lilly
Honoraria - Sanofi
Research Funding - Sanofi
Robert J. Mayer
No relevant relationships to disclose
Richard L. Schilsky
No relevant relationships to disclose
Monica M. Bertagnolli
No relevant relationships to disclose
Charles David Blanke
No relevant relationships to disclose